Table 3.

Ongoing clinical trials in HCC

Trial registration number	Description	Line of therapy
NCT02576509	Nivolumab vs. sorafenib	First
NCT02645981	Donafenib vs. sorafenib	First
NCT01737827	Capmatinib dose determination study	First
NCT01687673	Temsirolimus + sorafenib	First
NCT02524119	Ribociclib + chemoembolization	First
NCT02435433	Ramucirumab vs. placebo for patients with baseline AFP ≥ 400 ng/mL	Second
NCT02029157	Tivantinib vs. placebo for Japanese patients with high c-MET expression	Second
NCT01908426	Cabozantinib vs. placebo	Second
NCT02702401	Pembrolizumab vs. placebo	Second
NCT02329860	Apatinib vs. sorafenib	Second
NCT03062358	Pembrolizumab vs. placebo in Asian patients	Second
NCT02128958	CF-102 vs. placebo	Second
NCT02528643	Enzalutamide vs. placebo	Second
NCT02232633	BBI503	Second

The table shows selected phase 2 and 3 trials of systemic therapies for patients with hepatocellular carcinoma that are currently ongoing [28]

AFP α-fetoprotein